Ones To Watch News
Refine Search
Biotechnology
San Diego-based Rani Therapeutics Holdings, a biotherapeutics company focused on the oral delivery of biologics and drugs, has entered into a collaboration and license agreement with Chugai, a Chinese pharma that is majority owned by Roche. 20 October 2025
Biotechnology
Mosaic Therapeutics has named Thomas Fuchs as chief executive to lead the Cambridge-based oncology biotech through its transition into clinical development and a planned series B fundraising round. He succeeds interim chief executive Magda Jonikas, who will remain on the board as a non-executive director. 20 October 2025
Pharmaceutical
UK start-up Cyclana Bio has secured £5 million ($6.1 million) in pre-seed funding to advance its platform targeting women’s health through tissue-level therapeutics, starting with endometriosis. The round was co-led by NfX and Eka VC, with participation from Cocoa VC, Wilbe, and several angel investors. 20 October 2025
Biotechnology
CNS specialist Lundbeck and fellow Denmark based Contera Pharma today announced a strategic research collaboration aiming to accelerate the discovery and development of innovative oligonucleotide-based medicines for patients living with serious neurological conditions, where significant unmet medical needs remain. 20 October 2025
Pharmaceutical
Isotope Technologies Munich (ITM) has announced a higher objective response rate (ORR) and prolonged median progression-free survival (mPFS) across subgroups in patients treated with non-carrier-added (nca) 177Lu-edotreotide—also known as ITM-11 or 177Lu-edotreotide—compared to everolimus from its Phase III COMPETE trial in Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 18 October 2025
Pharmaceutical
USA-based Praxis Precision Medicines, a biopharma translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, has announced positive topline results for the Phase III Essential3 program of ulixacaltamide in essential tremor (ET). 17 October 2025
Biotechnology
Chinese biotech Kelun-Biotech has gained approval from the National Medical Products Administration for trastuzumab botidotin (A166), its HER2-targeted antibody-drug conjugate for patients with unresectable or metastatic HER2-positive breast cancer who have received at least one prior therapy. 17 October 2025
Biotechnology
US clinical-stage autoimmune diseases focused biotech Dianthus Therapeutics revealed it has entered into an exclusive licensing agreement with China’s Nanjing Leads Biolabs for DNTH212 (being developed in China by Leads Biolabs as LBL-047), a first and potentially best-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor. 17 October 2025
Pharmaceutical
USA-based clinical-stage dermatology start-up Veradermics has announced the completion of an oversubscribed $150 million Series C financing. 17 October 2025
Biotechnology
Chicago, USA-based biotech EVOQ Therapeutics has announced a collaboration and license agreement with French pharma major Sanofi to develop autoimmune disease therapies using NanoDisc technology, focusing on restoring immune tolerance. 16 October 2025
Biotechnology
European private equity firm Andera Partners announced that it has co-led the Series A financing round of Adcytherix, a French biotech start-up developing novel and proprietary antibody drug conjugates (ADC). 16 October 2025
Biotechnology
Los Angeles, USA-based biotech Pelage Pharmaceuticals has announced the close of a $120 million Series B financing. 16 October 2025
Biotechnology
Chinese biotech Xuanzhu Biopharmaceutical has raised over HK$780 million ($100 million) through its debut on the Hong Kong Stock Exchange. The public tranche was oversubscribed more than 4,900 times, making it one of the most popular new listings of the year. 16 October 2025
Pharmaceutical
California start-up Graph AI has raised $3 million in a seed round led by Bessemer Venture Partners, with the cash to accelerate product development, expand its engineering base, and build international presence. The company’s platform aims to overhaul how pharmaceutical firms manage regulatory-mandated drug safety monitoring. 16 October 2025
Biotechnology
German biotech Tubulis has closed a 308 million euro ($361 million) series C financing, marking the largest round of its kind for a European biotech and the biggest financing to date for a private antibody-drug conjugate (ADC) developer worldwide. 16 October 2025
Pharmaceutical
UK-based weight loss treatment company Oxford Medical Products is targeting 2027 for the commercial release of its hydrogel-based weight loss pill, Sirona. 15 October 2025
Biotechnology
Swiss clinical-stage biotech Alentis Therapeutics today announced the appointment of Dr Mark Pruzanski, as the company’s new chief executive (CEO), replacing Dr Roberto Iacone. 15 October 2025
Pharmaceutical
Shares of Omeros Corp skyrocketed 155% to $10.43 this morning, following the news of an asset purchase agreement with Novo Nordisk, as the Danish diabetes and obesity giant continues its spree of licensing and M&A deal-making to expand its portfolio. 15 October 2025
Pharmaceutical
US cardiovascular specialist Kardigan has announced the closing of a $254 million Series B financing. 15 October 2025
Biotechnology
Portuguese antibody discovery specialist FairJourney Biologics has named Werner Lanthaler as chief executive, replacing founder António Parada after nearly 14 years in charge. Mr Parada will join the supervisory board to steer innovation strategy while the company focuses on scaling globally. 15 October 2025
Biotechnology
Link Cell Therapies, an oncology cell therapy company, has announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson. 15 December 2025
Biotechnology
California-based Tenaya Therapeutics, a biotech seeking to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, has announced the pricing of a $60 million public offering. 15 December 2025
Biotechnology
US biopharma Arcus Biosciences has announced the discontinuation of the Phase III STAR-221 study, being conducted in partnership with Gilead Sciences (Nasdaq: GILD), due to futility. 15 December 2025
Biotechnology
Swedish Orphan Biovitrum, also known as Sobi, has entered into a definitive agreement to acquire San Diego, USA-based biotech Arthrosi Therapeutics, a private late-stage biotechnology company focused on developing a next-generation treatment for gout. 15 December 2025
Pharmaceutical
British pharma major AstraZeneca has joined a near-$100 million series A and A+ financing round for Syneron Bio, a biotechnology startup focused on macrocyclic peptide therapies for oncology and chronic diseases. 12 December 2025
Pharmaceutical
Danish biotech Sidera Bio has raised about 700 million kroner ($109 million) in a series A financing, one of the largest early-stage biotech rounds ever completed in Denmark. Investors include Novo Holdings, Forbion, RA Capital Healthcare Fund and Gilde Healthcare. 12 December 2025
Pharmaceutical
New York, USA-based rare disease firm Applied Therapeutics has announced a definitive agreement to be acquired by privately-held UK-based Cycle Pharmaceuticals. 12 December 2025
Biotechnology
US late-stage rare disease focused pharma Rezolute announced disappointing top-line results from its Phase III sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI) with news sending its shares crashing 87% to $1.40 by close of trading yesterday. 12 December 2025
Biotechnology
California, USA-based biotech Prolynx, which is developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, has announced the closing of a $70 million Series A financing and the appointment of industry veteran Chris Boulton as chief executive (CEO). 12 December 2025
Biotechnology
Dutch privately-held company ProteoNic, a provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic technology has been licensed by Ginkgo Bioworks for use in a project awarded to Ginkgo by the Biomedical Advanced Research and Development Authority (BARDA). 11 December 2025
Pharmaceutical
As a physical embodiment of the ambition of Accord Healthcare to establish itself as a leader in the global health landscape, the company’s new office in Stockley Park, London, is as impressive as it gets. 11 December 2025
Pharmaceutical
German biotech Disco Pharmaceuticals has appointed Mark Manfredi as chief executive and closed a 36 million euro ($39 million) seed round to advance its surfaceome-targeted pipeline. The financing was co-led by Ackermans & van Haaren and NRW.Bank with backing from Sofinnova Partners, AbbVie Ventures, M Ventures and Panakes Partners. 11 December 2025
Pharmaceutical
PsiThera has closed a $47.5 million series A round to advance oral therapies for immune and inflammatory diseases. The company also named former Seres Therapeutics chief executive Eric Shaff as chief executive. 11 December 2025
Pharmaceutical
Hong Kong-based Ascletis Pharma has announced that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor for the treatment of moderate-to-severe acne vulgaris, has been accepted by the China National Medical Products Administration (NMPA). 11 December 2025
Pharmaceutical
Privately-held BlossomHill Therapeutics, a US biopharma focused on the design and development of next-generation medicines for cancer, has announced the closing of an $84 million Series B extension, bringing total capital raised by the company to $257 million to date. 10 December 2025
Biotechnology
US AI-focused start-up Formation Bio has entered a deal with Lynk Pharmaceuticals for worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The asset will be developed within Formation's newly formed subsidiary Bleecker Bio. 10 December 2025
Pharmaceutical
Switzerland’s Idorsia announced the publication of a new analysis from the landmark Phase III PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant Hypertension”. The analysis examined the efficacy and safety of aprocitentan (trade names Tryvio and Jeraygo) in patients with chronic kidney disease (CKD) and confirmed resistant hypertension – a population with very limited treatment options and high cardiovascular and renal risk. 10 December 2025
Biotechnology
Privately-held UK biotech Relation Therapeutics has announced a multi-program, strategic collaboration with Swiss pharma giant Novartis to discover and advance novel targets for atopic diseases. 9 December 2025
Biotechnology
German contract development and manufacturing company ProBioGen and Spica Therapeutics, a pioneering Belgian biotech advancing pathogenic macrophage subset-targeted immunotherapies, today announced a new collaboration. 9 December 2025
Biotechnology
Sanegene Bio has raised more than $110 million in a series B round to move its RNAi programs toward registration studies and broaden development across metabolic, cardiovascular and autoimmune diseases. The financing comes as global RNA-based medicines gain momentum and investors show renewed confidence in advanced delivery platforms. 9 December 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A TechBio company that specializes in developing personalized vaccines and immunotherapies through its advanced AI-Immunology™ platform. The company bridges artificial intelligence technology, bioinformatics, and drug development to bring novel immunotherapies to patients facing cancer and infectious diseases.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze